The Hydration Pharmaceuticals Co Ltd (ASX: HPC) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

The Hydration Pharmaceuticals Co Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $3.05 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 304.91 million
Earnings per share -0.040
Dividend per share N/A
Year To Date Return -62.50%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • The Hydration Pharmaceuticals Co Ltd (ASX: HPC)
    Latest News

    Young girl wearing glasses flexes her left bicep confidently.
    Opinions

    "Bullish because everybody is bearish" – here are 8 dogs of 2022 I'm backing for the win in 2023 

    These 8 ASX microcap stocks could bounce back in 2023.

    Read more »

    A man has a big smile on his face as he pours water over his head.
    IPOs

    Hydration Pharmaceuticals (ASX:HPC) share price rockets 31% in 2 days following IPO

    Here's all you need to know about the ASX newbie.

    Read more »

    HPC ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About The Hydration Pharmaceuticals Co Ltd

    The Hydration Pharmaceuticals Co Ltd is engaged in the marketing and sale of liquid, tablet and powder hydration solution products into the North American markets of Canada and the United States. Some of its products include Hydration + Immune System Boost, Effervescent Electrolyte Tablets, Oral Rehydration Solution, and Immunity Booster Bundle.

    HPC Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    14 Jun 2024 $0.01 $0.00 0.00% 252,072 $0.01 $0.01 $0.01
    13 Jun 2024 $0.01 $0.00 0.00% 250,000 $0.01 $0.01 $0.01
    11 Jun 2024 $0.01 $0.00 0.00% 111,160 $0.01 $0.01 $0.01
    06 Jun 2024 $0.01 $0.00 0.00% 620,690 $0.01 $0.01 $0.01
    05 Jun 2024 $0.01 $0.00 0.00% 373,374 $0.01 $0.01 $0.01
    04 Jun 2024 $0.01 $0.00 0.00% 527,736 $0.01 $0.01 $0.01
    03 Jun 2024 $0.01 $0.00 0.00% 1,542,414 $0.01 $0.01 $0.01
    31 May 2024 $0.01 $0.00 0.00% 750,540 $0.01 $0.01 $0.01
    30 May 2024 $0.01 $0.00 0.00% 99,687 $0.01 $0.01 $0.01
    29 May 2024 $0.01 $0.00 0.00% 2,795,712 $0.01 $0.01 $0.01
    28 May 2024 $0.01 $0.00 0.00% 899,794 $0.01 $0.01 $0.01
    27 May 2024 $0.01 $0.00 0.00% 592,640 $0.01 $0.01 $0.01
    24 May 2024 $0.01 $0.00 0.00% 409,837 $0.01 $0.01 $0.01
    23 May 2024 $0.01 $0.00 0.00% 599,181 $0.01 $0.01 $0.01
    22 May 2024 $0.01 $0.00 0.00% 448,418 $0.01 $0.01 $0.01
    21 May 2024 $0.01 $0.00 0.00% 339,316 $0.01 $0.01 $0.01

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    02 Oct 2023 Adem Karafili Issued 500,000 $19,000
    Rights issue.
    02 Oct 2023 Adem Karafili Issued 1,000,000 $45,000
    Rights issue.
    02 Oct 2023 Margaret Hardin Issued 333,333 $14,999
    Rights issue.
    02 Oct 2023 Margaret Hardin Issued 166,667 $6,333
    Rights issue.
    20 Sep 2023 George Livery Issued 277,778 $10,833
    Rights issue.
    20 Sep 2023 George Livery Issued 555,555 $24,999
    Rights issue.
    08 Aug 2023 Adem Karafili Issued 1,972 $423
    Issue of securities.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Adem Karafili Non-Executive DirectorNon-Executive Chairman Oct 2018
    Mr Adem is the Chairman and founder of ANGL Korp, his investment vehicle for both ventures and investments. In his previous career, Adem was across a range of sectors and industries, having spent seven years establishing Swisse Wellness as the global health and wellness brand before it's sale to Biostime International for over $1.7bn. While at Swisse, Adem held senior positions of Chief Financial Officer, Chief Operating Officer, and Managing Director.
    Mr Oliver Baker Chief Executive OfficerManaging Director May 2024
    Mr Baker is the CEO of Hydralyte North America, having joined the business in 2018, taking responsibility for global sales. Prior to the Company, he worked at Swisse Wellness in a number of roles across business development, marketing and general management. After the Biostime (H&H Group) acquisition of Swisse, he led the integration team in Guangzhou China, building a local Chinese team and processes. He was then appointed General Manager of Swisse North America and was responsible for the launch of the Swisse brand with an e-commerce focused strategy in the USA and Canada. Previously he has held global and national roles in sales and marketing with a focus on sports sponsorships.
    Ms Margaret Hardin Non-Executive Director Feb 2022
    Ms Hardin is a global products senior executive, with experience. She has previously scaled two consumer goods companies to generate more than US$100m in revenue, and currently advises founders on growth opportunities. Most recently, Ms Hardin was CEO of ERGObaby Carrier Inc. During her time with the group, she revived product innovation while managing an omni-channel distributor, retail, and ecommerce model across over 60 countries and 19 company-owned websites. Prior to ERGObaby Carrier Inc., Ms Hardin was CFO during the early stages of US baby and accessories company Munchkin and was progressively promoted to President and COO. She grew the company to a brand leader in the juvenile industry, where she led sales, acquisitions, brand partnerships and marketing efforts. She oversaw the opening of sales operations in Canada and launched the EMEA headquarters.
    Mr Nick Berry Non-Executive Director May 2024
    Mr Berry brings over 19 years of experience in the Australian finance industry, in equity and debt capital markets, mergers and acquisitions and strategic planning. He previously served as an Executive Director at Nomura Australia and is currently a Director of PURE Asset Management Pty Ltd.
    Ms Victoria Nadalin Company Secretary Feb 2023
    -
    Chris Kavanaugh CFO
    -
    Victoria Nadalin Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    J P Morgan Nominees Australia Pty Limited 36,950,920 13.94%
    Merrill Lynch (Australia) Nominees Pty Limited 27,325,447 10.31%
    Woobinda Nominees Pty Ltd <The Woobinda Family A/C> 26,901,678 10.15%
    HSBC Custody Nominees (Australia) Limited 20,453,824 7.71%
    Super Radek Pty Ltd <Super Radek Super Fund A/C> 12,316,113 4.65%
    Paul Orlin 7,732,978 2.92%
    343 Pty Ltd <343 Capital A/C> 7,126,416 2.69%
    Binvid Pty Ltd <B&D Super Fund A/C> 6,332,787 2.39%
    Citicorp Nominees Pty Limited 5,470,977 2.06%
    Bnp Paribas Nominees Pty Ltd <Ib Au Noms Retailclient> 4,157,435 1.57%
    Bw Equities Pty Ltd 4,143,104 1.56%
    Mr Carlo Chiodo 2,941,553 1.11%
    Ff Investments Nz Limited 2,901,462 1.09%
    Gowings Whale Fund Pty Ltd <Gowings Whale A/C> 2,797,992 1.06%
    Ankara Holdings Pty Ltd <The Ankara Family A/C 2,562,389 0.97%
    Tahmedia Pty Ltd 2,329,307 0.88%
    Ilwella Pty Ltd <No 2 A/C> 2,300,000 0.87%
    Netwealth Investments Limited <Wrap Services A/C> 1,979,253 0.75%
    Netwealth Investments Limited <Super Services A/C> 1,968,166 0.74%
    Richjac Pty Ltd 1,843,263 0.70%

    Profile

    since

    Note